UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Respiratory allergy caused by house dust mites: What do we really know?

Journal of allergy and clinical immunology, 2015-07, Vol.136 (1), p.38-48

2015

Volltextzugriff (PDF)

Benralizumab strongly reduces blood basophils in severe eosinophilic asthma

Clinical and experimental allergy, 2020-11, Vol.50 (11), p.1267-1269

2020

Volltextzugriff (PDF)

Against all odds: anti-IgE for intrinsic asthma?

Thorax, 2014-01, Vol.69 (1), p.94-96

2014

Volltextzugriff (PDF)

Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation

American journal of respiratory and critical care medicine, 1998-12, Vol.158 (6), p.2002-2005

1998

Volltextzugriff (PDF)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER

Respiratory research, 2020-10, Vol.21 (1), p.1-285, Article 285

2020

Volltextzugriff (PDF)

The impact of age, weight and gender on BDNF levels in human platelets and plasma

Neurobiology of aging, 2005, Vol.26 (1), p.115-123

2005

Volltextzugriff (PDF)

Comparison of volume- and pressure-limited NPPV at night: a prospective randomized cross-over trial

Respiratory medicine, 2005, Vol.99 (1), p.52-59

2005

Volltextzugriff (PDF)

Outcome of Patients With Stable COPD Receiving Controlled Noninvasive Positive Pressure Ventilation Aimed at a Maximal Reduction of Paco2

Chest, 2005-08, Vol.128 (2), p.657-662

2005

Volltextzugriff (PDF)

House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2015-11, Vol.3 (6), p.843-855

2015

Volltextzugriff (PDF)

Specific immunotherapy-indications and mode of action

Deutsches Ärzteblatt international, 2013-03, Vol.110 (9), p.148-158

2013

Volltextzugriff (PDF)

COVID‐19 in a patient with severe asthma treated with Omalizumab

Allergy (Copenhagen), 2020-10, Vol.75 (10), p.2705-2708

2020

Volltextzugriff (PDF)

Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Asthma Control in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB210-AB210

2016

Volltextzugriff (PDF)

Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB213-AB213

2016

Volltextzugriff (PDF)

Normal Blood Eosinophil Counts in Humans

Respiration, 2024, Vol.103 (4), p.214

2024

Volltextzugriff (PDF)

Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult‐onset than in severe early‐onset asthma

Allergy (Copenhagen), 2021-10, Vol.76 (10), p.3199-3202

2021

Volltextzugriff (PDF)

The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma

The Journal of experimental medicine, 2003-08, Vol.198 (3), p.455-467

2003

Volltextzugriff (PDF)

Biologics and airway remodeling in severe asthma

Allergy (Copenhagen), 2022-12, Vol.77 (12), p.3538-3552

2022

Volltextzugriff (PDF)

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

The Lancet (British edition), 2019-11, Vol.394 (10210), p.1737-1749

2019

Volltextzugriff (PDF)

Disease-modifying anti-asthmatic drugs

The Lancet (British edition), 2022-04, Vol.399 (10335), p.1664-1668

2022

Volltextzugriff (PDF)

In Reply

Deutsches Ärzteblatt international, 2015-08

2015

Volltextzugriff (PDF)

Extrafine triple therapy in patients with asthma and persistent airflow limitation

The European respiratory journal, 2020-09, Vol.56 (3), p.2000476

2020

Volltextzugriff (PDF)

Advancing precision medicine in asthma: Evolution of treatment outcomes

Journal of allergy and clinical immunology, 2023-10, Vol.152 (4), p.835-840

2023

Volltextzugriff (PDF)

Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses

Journal of allergy and clinical immunology, 2021-07, Vol.148 (1), p.262-265.e2

2021

Volltextzugriff (PDF)

Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations

Allergy (Copenhagen), 2022-09, Vol.77 (9), p.2839-2843

2022

Volltextzugriff (PDF)

Safety of segmental allergen challenge in human allergic asthma

Journal of allergy and clinical immunology, 2008-03, Vol.121 (3), p.712-717

2008

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Humans
(41)
Asthma
(27)
Respiratory System
(24)
Immunology
(22)
Adult
(17)
Female
(17)
Male
(17)
Allergy
(13)
Middle Aged
(13)
Biological And Medical Sciences
(12)
Medical Sciences
(11)
Asthma - Drug Therapy
(10)
Aged
(9)
Patients
(9)
Asthma - Immunology
(8)
Chronic Obstructive Pulmonary Disease
(8)
General & Internal Medicine
(8)
Allergy And Immunology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Respiratory allergy caused by house dust mites: What do we really know?

Benralizumab strongly reduces blood basophils in severe eosinophilic asthma

Against all odds: anti-IgE for intrinsic asthma?

Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER

The impact of age, weight and gender on BDNF levels in human platelets and plasma

Comparison of volume- and pressure-limited NPPV at night: a prospective randomized cross-over trial

Outcome of Patients With Stable COPD Receiving Controlled Noninvasive Positive Pressure Ventilation Aimed at a Maximal Reduction of Paco2

House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies

Specific immunotherapy-indications and mode of action

COVID‐19 in a patient with severe asthma treated with Omalizumab

Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Asthma Control in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels

Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels

Normal Blood Eosinophil Counts in Humans

Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult‐onset than in severe early‐onset asthma

The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma

Biologics and airway remodeling in severe asthma

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

Disease-modifying anti-asthmatic drugs

In Reply

Extrafine triple therapy in patients with asthma and persistent airflow limitation

Advancing precision medicine in asthma: Evolution of treatment outcomes

Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses

Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations

Safety of segmental allergen challenge in human allergic asthma

Suchergebnisse filtern